Global Migraine Market Report: 2016 Edition - New Report by Koncept Analytics - PowerPoint PPT Presentation

Loading...

PPT – Global Migraine Market Report: 2016 Edition - New Report by Koncept Analytics PowerPoint presentation | free to download - id: 818b88-M2UwM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Global Migraine Market Report: 2016 Edition - New Report by Koncept Analytics

Description:

The report, “Global Migraine Market” analyzes the currently prevailing condition of the market. For more mail: vikas@konceptanalytics.com – PowerPoint PPT presentation

Number of Views:2

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Global Migraine Market Report: 2016 Edition - New Report by Koncept Analytics


1
Global Migraine Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details
  • Executive Summary
  • Migraine is a common neurovascular disorder that
    is characterized by throbbing headaches and is
    commonly associated with other neurological
    symptoms, such as nausea, vomiting, and painful
    sensitivity to lights and sounds. Migraines are
    thought to result from the activation and
    sensitization of sensory neurons that have nerve
    endings in meningeal blood vessels. Migraines can
    be episodic or chronic. Chronic Migraine (CM) and
    Episodic Migraine (EM) are both part of the
    spectrum of migraine disorders, but are distinct
    clinical entities. The onset of migraine is
    preceded by certain triggers, which can be unique
    for each migraine sufferer.
  • Triptans and Ergots are among the most common
    drug options existing in the treatment market for
    migraine. The global migraine treatment market
    currently faces several unmet needs and is
    saturated with the availability of generic drugs.
    Several branded drugs are under development with
    safer and more effective profiles, given the vast
    opportunities existing in the market. The focus
    of upcoming drugs is to either cure migraine or
    to reduce the frequency to a level where patients
    can find tolerable relief.
  • The migraine market is expected to acquire modest
    growth driven by launch of new therapies and
    increasing rate of drug treatment due to
    increasing female population and rising awareness
    among physicians and patients. The major growth
    drivers of the migraine market includes rising
    spending on medicines, growing female population,
    increasing cigarette consumption and healthcare
    expenditure. However, the growth of the market
    will also remain challenged by complications
    associated with Triptans, treatment limitations
    for patients with CV (Cardio Vascular) risk and
    increased preference for OTC (Over the Counter)
    medications.
  • The report, Global Migraine Market analyzes the
    currently prevailing condition of the market
    along with its future scope of development. The
    specific market of the U.S. is being discussed in
    the report. The major trends, growth drivers as
    well as issues being faced by the industry are
    being presented in this report. The major players
    in the industry are being profiled, along with
    their key financials and strategies for growth.

3
Among several drug options existing in the
market, Triptans and Ergots are the most common
treatment options available for migraine
Global Migraine Drug Market by Value (2013-2020E)
  • The overall market for migraine drug is estimated
    to have reached US.. billion in the year 2015,
    increasing from US.. billion in year 2013. The
    drug market for migraine is further expected to
    reach US.. billion and US.. billion in year
    2017 and 2020 respectively.
  • Nearly, of the global migraine treatment
    market is estimated to have been made up of
    medications based on active substance called
    Triptans in year 2015. The second group which
    accounted for nearly comprises medications
    based on Dihydroergotamine (DHE).
  • In 2015, nearly .. share of the therapeutic
    Botulinum toxin market represented treatment of
    chronic migraine followed by cervical dystonia
    and overactive bladder holding and share
    respectively.

Global Migraine Drug Market by Category (2015E)
Global Therapeutic Botulinum Toxin Market by
Indication (2015)
4
The driving forces for growth of Migraine
market includes several innovations in medication
delivery, increased level of awareness of
migraine among doctors and patients combined with
innovation in delivery of clinically proven
marketed medications
The U.S. Total Migraine Population (2015-2022E)
  • The U.S. migraine population is expected to reach
    million by the end of year 2022, increasing
    from million in 2015, on account of rising
    awareness among patients physicians and
    increasing migraine prevalence.
  • Of .. million migraine population in the U.S.,
    nearly .. million (..) cases got diagnosed
    followed by nearly .. million (..) undiagnosed
    cases. Out of the million diagnosed cases,
    nearly million (..) cases were for prevention,
    while rest .. million (..) cases were not for
    prevention.
  • Of the total candidates for prevention therapy in
    the U.S. in year 2015, nearly .. of the
    candidates were treated by neurologists. However,
    nearly .. of the prevention candidates got
    primary care treatment for the given year.

The U.S. Migraine Population by Diagnosis (2015E)
The U.S. Preventive Migraine Treatment by
Specialty (2015)
5
The U.S. migraine treatment market currently
faces several unmet needs. The current treatment
patterns necessitate introduction of new
therapies that are safer and more effective,
compared to currently available therapies
The U.S. Migraine Population with CV Risk Factors
(2015-2022E)
  • In 2015, nearly .. or .. million patients of the
    total migraine patients in the U.S. had
    cardiovascular risk factors. Triptans were
    contraindicated in approximately .., or ..
    million patients. In addition, another .. of the
    migraine patients were at a risk for silent
    myocardial ischemia for the given year.
  • Among the treated adult migraine patients in the
    U.S., nearly .. patients received Triptans
    during 2014. Of the .. Triptans treated
    population nearly .. were treated from Triptans
    only, .. from combination of Triptans
    Prophylaxis and .. with Triptans other acute
    classes.
  • The prescription volume for acute migraine in the
    U.S. reached million in the year 2015, with as
    estimation of reaching million prescriptions by
    the end of year 2025.

The U.S. Acute Migraine Treated Population by
Drug Type (2014)
The U.S. Acute Migraine Prescription Volume
(2015-2025E)
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Migraine Market . To know more about this report
or for any customized research requirement,
please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com
About PowerShow.com